140 related articles for article (PubMed ID: 10435621)
1. Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors.
Bilanges B; Varrault A; Basyuk E; Rodriguez C; Mazumdar A; Pantaloni C; Bockaert J; Theillet C; Spengler D; Journot L
Oncogene; 1999 Jul; 18(27):3979-88. PubMed ID: 10435621
[TBL] [Abstract][Full Text] [Related]
2. Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities.
Bilanges B; Varrault A; Mazumdar A; Pantaloni C; Hoffmann A; Bockaert J; Spengler D; Journot L
Oncogene; 2001 Mar; 20(10):1246-53. PubMed ID: 11313869
[TBL] [Abstract][Full Text] [Related]
3. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas.
Pagotto U; Arzberger T; Theodoropoulou M; Grübler Y; Pantaloni C; Saeger W; Losa M; Journot L; Stalla GK; Spengler D
Cancer Res; 2000 Dec; 60(24):6794-9. PubMed ID: 11156367
[TBL] [Abstract][Full Text] [Related]
4. The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas.
Basyuk E; Coulon V; Le Digarcher A; Coisy-Quivy M; Moles JP; Gandarillas A; Journot L
Mol Cancer Res; 2005 Sep; 3(9):483-92. PubMed ID: 16179495
[TBL] [Abstract][Full Text] [Related]
5. Loss of expression of ZAC/LOT1 in squamous cell carcinomas of head and neck.
Koy S; Hauses M; Appelt H; Friedrich K; Schackert HK; Eckelt U
Head Neck; 2004 Apr; 26(4):338-44. PubMed ID: 15054737
[TBL] [Abstract][Full Text] [Related]
6. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
[TBL] [Abstract][Full Text] [Related]
7. Krüppel-like factor 6 is frequently down-regulated and induces apoptosis in non-small cell lung cancer cells.
Ito G; Uchiyama M; Kondo M; Mori S; Usami N; Maeda O; Kawabe T; Hasegawa Y; Shimokata K; Sekido Y
Cancer Res; 2004 Jun; 64(11):3838-43. PubMed ID: 15172991
[TBL] [Abstract][Full Text] [Related]
8. Loss of expression of ZAC/PLAGL1 in diffuse large B-cell lymphoma is independent of promoter hypermethylation.
Valleley EM; Cordery SF; Carr IM; MacLennan KA; Bonthron DT
Genes Chromosomes Cancer; 2010 May; 49(5):480-6. PubMed ID: 20175198
[TBL] [Abstract][Full Text] [Related]
9. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer.
Chen C; Bhalala HV; Qiao H; Dong JT
Oncogene; 2002 Sep; 21(43):6567-72. PubMed ID: 12242654
[TBL] [Abstract][Full Text] [Related]
10. RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis.
Oh JJ; Taschereau EO; Koegel AK; Ginther CL; Rotow JK; Isfahani KZ; Slamon DJ
Lung Cancer; 2010 Dec; 70(3):253-62. PubMed ID: 20338664
[TBL] [Abstract][Full Text] [Related]
11. SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers.
Dallol A; Da Silva NF; Viacava P; Minna JD; Bieche I; Maher ER; Latif F
Cancer Res; 2002 Oct; 62(20):5874-80. PubMed ID: 12384551
[TBL] [Abstract][Full Text] [Related]
12. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers.
Filippova GN; Lindblom A; Meincke LJ; Klenova EM; Neiman PE; Collins SJ; Doggett NA; Lobanenkov VV
Genes Chromosomes Cancer; 1998 May; 22(1):26-36. PubMed ID: 9591631
[TBL] [Abstract][Full Text] [Related]
13. SASH1: a candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer.
Zeller C; Hinzmann B; Seitz S; Prokoph H; Burkhard-Goettges E; Fischer J; Jandrig B; Schwarz LE; Rosenthal A; Scherneck S
Oncogene; 2003 May; 22(19):2972-83. PubMed ID: 12771949
[TBL] [Abstract][Full Text] [Related]
14. Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas.
Toyooka KO; Toyooka S; Virmani AK; Sathyanarayana UG; Euhus DM; Gilcrease M; Minna JD; Gazdar AF
Cancer Res; 2001 Jun; 61(11):4556-60. PubMed ID: 11389090
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.
Lai J; Flanagan J; Phillips WA; Chenevix-Trench G; Arnold J
Br J Cancer; 2003 Jan; 88(2):270-6. PubMed ID: 12610513
[TBL] [Abstract][Full Text] [Related]
16. Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer.
Fujii H; Biel MA; Zhou W; Weitzman SA; Baylin SB; Gabrielson E
Oncogene; 1998 Apr; 16(16):2159-64. PubMed ID: 9572497
[TBL] [Abstract][Full Text] [Related]
17. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific imprinting of the ZAC/PLAGL1 tumour suppressor gene results from variable utilization of monoallelic and biallelic promoters.
Valleley EM; Cordery SF; Bonthron DT
Hum Mol Genet; 2007 Apr; 16(8):972-81. PubMed ID: 17341487
[TBL] [Abstract][Full Text] [Related]
19. CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3.
Kochetkova M; McKenzie OL; Bais AJ; Martin JM; Secker GA; Seshadri R; Powell JA; Hinze SJ; Gardner AE; Spendlove HE; O'Callaghan NJ; Cleton-Jansen AM; Cornelisse C; Whitmore SA; Crawford J; Kremmidiotis G; Sutherland GR; Callen DF
Cancer Res; 2002 Aug; 62(16):4599-604. PubMed ID: 12183414
[TBL] [Abstract][Full Text] [Related]
20. Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma.
Sathyanarayana UG; Padar A; Huang CX; Suzuki M; Shigematsu H; Bekele BN; Gazdar AF
Clin Cancer Res; 2003 Dec; 9(17):6389-94. PubMed ID: 14695139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
